Investment outlooks for 2026 and A-share target prices from foreign institutions including Morgan Stanley, Morgan Stanley China (‘Xiao Mo’), and UBS

According to available information, OmniVision Technologies (OV) is a fabless semiconductor design company engaged in chip design. Per market research firm TrendForce, OV ranks among the world’s top ten fabless semiconductor companies. Its semiconductor design and sales business comprises three core segments: image sensor solutions, display solutions, and analog solutions. Recently, OV launched its new OV50R CMOS image sensor, featuring a 1/1.3-inch optical format, 50-megapixel resolution, and 1.2μm pixel size—positioned for premium main-camera applications across smartphones, action cameras, vlog cameras, and portable cameras. The OV50R has completed sampling and is scheduled to enter mass production in Q1 2026, potentially further enhancing OV’s penetration in the high-end imaging market. JPMorgan forecasts OV’s net profit growth at 33.82% for 2025 and 40.05% for 2026. UBS: Global tech stocks set for a new rally in 2026! Upgraded ratings to 'Buy' for four companies! In its 2026 Investment Outlook, UBS states that the A-share market stands at a positive inflection point of earnings growth and valuation re-rating. It expects A-share earnings growth to accelerate from 6% this year to 8% next year. This acceleration is driven by two key factors: first, faster nominal GDP growth coupled with a narrowing year-on-year decline in the Producer Price Index (PPI) is expected to jointly boost listed companies’ revenues; second, the implementation of a series of supportive macro policies and sustained healthy deleveraging within the corporate sector may drive a modest recovery in overall profitability. Moreover, the current A-share equity risk premium—above its historical average—implies significant potential for valuation re-rating. Additionally, recent market corrections stem primarily from global tech-sector adjustments and short-term trading congestion—but present an excellent opportunity to position for medium-term re-rating logic. UBS’s Global Strategy Team believes global tech stocks will enter a new upswing in 2026. Investment recommendations focus on four themes: technological self-reliance, consumption recovery, sectors benefiting from 'anti-internal competition' policies (e.g., photovoltaics, lithium batteries, chemicals), and Chinese enterprises expanding overseas. Key risks include escalation of U.S.-China trade tensions, continued property-sector weakness, and a potential global AI bubble burst. Our analysis shows that since October this year, UBS has issued updated ratings for 196 A-share companies: maintaining 'Buy' ratings for 131, upgrading four to 'Buy', and one to 'Neutral'. UBS also initiated coverage on 15 companies for the first time—including Great Wall Motor, EdiGene Biotechnologies, and Longhua Technology—with 'Buy' ratings for all three. Regarding target price upside, UBS’s latest target price for Aipu Medical is RMB 118 per share, compared to its closing price of RMB 61.28 on December 5—implying over 90% upside potential. Morgan Stanley, Goldman Sachs, and Citigroup: A-share valuations remain attractive! Stock selection is critical! Wang Ying, Chief China Equity Strategist at Morgan Stanley, notes that in 2025, China’s equity market completed a decisive valuation recovery—driven by strengthened confidence from consumption support and 'anti-internal competition' policies, growing global recognition of Chinese enterprises’ competitiveness, and marginal improvement in the geopolitical environment. The MSCI China Index P/E ratio rebounded from 9x to over 13x.

UBS 2026 Annual Outlook: Bullish on China, bullish on biotech

2. U.S. equities: Still a core holding—but no longer the world’s strongest market. S&P 500 earnings are forecast at USD 305 per share; year-end target: 7,700 points (a ~17% rise from the current level of ~6,600). Top four preferred sectors: ① Technology (AI-driven), ② Utilities (explosive electricity demand), ③ Healthcare (freed from policy uncertainty + GLP-1 obesity drug cycle), ④ Banking (improving net interest margins + regulatory easing). The report explicitly states: The U.S. is no longer dominant—the U.S. underperformed both China and Europe in 2025. 3. Thematic investment trend #1: AI. Viewed as the only sufficiently powerful new engine capable of achieving 'escape velocity.' 2026 marks the pivotal year when AI transitions from 'large-scale infrastructure build-out' to 'large-scale commercial monetization.' Recommended allocation: 30% of equity portfolios to the full AI value chain—enablers (chips/cloud/networking), intelligence layer (large language models), and applications (AI agents/customer service/healthcare/industrial). If AI progress meets expectations, global equities could easily rise >30%; if not, a 10–20% correction may follow. 4. Thematic investment trend #2: Power. The second major structural pillar—alongside AI. AI data centers, electrification, and re-industrialization will trigger unprecedented electricity demand: globally, annual new power generation capacity equivalent to 'two Californias' will be needed between 2026 and 2030. Top picks: transmission & distribution, nuclear/renewable power operators, data center infrastructure, energy storage, and grid modernization. Utility stocks are named top sector picks in both the U.S. and Europe. 5. Thematic investment trend #3: Longevity (biotech). A newly added third theme in the 2026 report. Weight-loss drugs (GLP-1 agonists) are merely the appetizer; over the next 5–10 years, revolutionary breakthroughs—including cellular repair, gene editing, immunotherapies, and brain-computer interfaces—will launch a 'super-cycle' of human longevity and health dividends. Top picks: innovative pharma companies, diagnostics, medical devices, and biotech platform firms. 6. Chinese equities: Among the world’s strongest alpha sources in 2026—warranting a dedicated chapter titled 'Seek Opportunities in China.' Rationale: ① China’s large language models and application layer have already achieved global leadership; ② Strong policy support for technological self-reliance and control; ③ A triple convergence of liquidity, earnings, and retail investor inflows began in 2025 and will continue into 2026; ④ Valuations remain significantly below global peers. Broadly defined Chinese equities (A-shares + H-shares + U.S.-listed Chinese stocks) are designated a 'world-class allocation opportunity.' 7. Gold: No longer singled out as a standalone top recommendation—but remains explicitly favored under 'Favor commodities.' Core rationale unchanged: central bank gold buying (de-dollarization), massive fiscal deficits, geopolitical risks, low real interest rates, and financial repression. Recommended allocation: 5%, serving as the most effective risk diversifier. Silver is similarly attractive. 8. U.S. Dollar: Continued weakness expected—and this weakness will persist longer. Reasons: U.S. twin deficits, monetary easing cycle, and financial repression (suppressing U.S. Treasury yields weakens dollar appeal). Most favored currencies against the USD: euro, Australian dollar, Norwegian krone; high-yield emerging-market currencies also benefit from rising risk appetite.

UBS Adjusts Price Target on DuPont de Nemours to $178 From $175, Maintains Buy Rating

Aug 5, 2026

UBS raised its price target for DuPont de Nemours to $178 and maintained a Buy rating following strong second-quarter 2026 earnings and a raised full-year profit outlook.

www.marketscreener.com

2026-04-21

UBS Raises Corteva Price Target to $88, Maintains Neutral Rating

2026-04-22

DuPont de Nemours Inc. Stock Underperforms vs Competitors on Wednesday

2026-04-24

DuPont’s Electronics Spinoff Qnity Prices $4.1B Debt Deal Ahead of November Split

2026-04-24

RBC Adjusts Price Target on DuPont de Nemours to $56 From $60, Maintains Outperform Rating

2026-04-28

Morgan Stanley Adjusts DuPont de Nemours Price Target to $52 From $44, Maintains Equal Weight Rating